

21 August 2017

Beta Testing Commences for Cloud-Based A.I. Prototype

Resonance Health (ASX: RHT) is pleased to announce it is commencing beta-testing of its ground breaking artificial intelligence (AI) solution for the rapid, low-cost analysis of liver-iron-concentration (LIC) that runs off the flagship FerriScan® protocol. Field testing of the first iteration of the cloud-based solution represents an important milestone for the Company as part of its strategy to increase market share in emerging growth markets.

This in situ beta testing will focus on evaluating the user-interface and usability of the new cloud-based AI service alongside FerriScan over a 30-day period. Following this, the beta-version will be refined and evaluated across multiple centres. This is scheduled to commence in the September quarter as the Company matures the product for commercial release.

The new AI tool will have application for Thalassemia patients who are over-represented in emerging growth markets. The World Health Organisation estimates that 330,000 people are born annually with haemoglobin disorders.

The results of the Dragon Study, in a paper presented in June of this year at the European Haematology Association (EHA) meeting in Madrid, publicised significant deficiencies in a highly used T2* method for the measurement of LIC. So significant were the conclusions, that the Thalassemia International Federation (TIF) issued a global alert warning on the dangers of using unregulated T2* tests for the MRI assessment of LIC. Use of unregulated T2* methods in emerging growth markets is widespread. FerriScan remains the only FDA cleared method for the MRI assessment of liver-iron-concentration.

Subject to successful beta testing, Resonance Health intends to leverage the accessibility and cost-effectiveness of the tool to position it as the solution of choice for the measurement of liver iron concentration in emerging growth markets. In developing this tool the Company will reduce existing cost barriers and improve product scalability in line with its emerging growth market strategy.

Further updates will be provided as work progresses.

Martin Blake

Chairman RHT

For further information please contact:

Sander Bangma

General Manager, Resonance Health

E: sanderb@resonancehealth.com P: +61 (0)8 9286 5300